Actuate Therapeutics (ACTU)

• Market cap: $50.7M
• 1 day: 4.43%
• 5 days: 9.28%
• 1 month: -12.76%
• 3 months: -23.47%
• 6 months: -69.1%
• Year to date: -64.84%
• 1 year: -72.72%
• 5 years: -75.38%
• 10 years: -75.38%
• Sector: Healthcare
• Industry: Biotechnology

About: Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Employees: 12